Table 4.
Select studies related to T790M mutation as a prognostic marker for patients with NSCLC
| Author/trial (year) | Number |
EGFR T790M mutation, n
|
PFS (months)
|
OS (months)
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| Mutation | Wild-type | Mutation | Wild-type | Mutation | Wild-type | ||||
| Oxnard et al (2011)91 | 93 | 58 (62.4%) | 35 (37.6%) | 19.0 | 12.0 | 39.0 | 26.0 | ||
| P=0.036 | P=0.007 | ||||||||
| Fujita et al (2012)92 | 38 | 30 (78.9%) | 8 (21.1%) | TTF | NR | ||||
| 9.0 | 7.0 | ||||||||
| P=0.44 | |||||||||
| Sun et al (2013)95 | 70 | 36 (51.4%) | 34 (48.6%) | 14.7 | 14.1 | 43.5 | 36.8 | ||
| P=0.26 | P=0.23 | ||||||||
| Kuiper et al (2014)93 | 66 | 34 (51.5%) | 32 (48.5%) | 14.2 | 11.1 | 45.9 | 29.8 | ||
| P=0.034 | P=0.213 | ||||||||
| Li et al (2014)94 | 54 | 29 (53.7%) | 25 (46.3%) | PFS1 | |||||
| 13.0 | 10.5 | ||||||||
| P=0.894 | |||||||||
| PFS2 | OS2 | ||||||||
| 6.3 | 2.6 | 39.8 | 23.2 | ||||||
| P=0.002 | P=0.044 | ||||||||
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; TTF, time to treatment failure; PFS, progression-free survival; PFS1, the time from the date of starting; PFS2, the time from the date of the first disease progression to the second disease progression; OS, overall survival; OS2, the time from the date of starting the therapy to death or last follow-up; NR, not reported.